A study in Life Metabolism shows that a single post-meal blood biomarker, 1-hour postprandial SPARC, predicts who benefits most from a Mediterranean diet. Lower baseline SPARC-1H levels were linked to greater improvements in insulin resistance and glucose control in a six-month trial.
Global oncology drug spending is projected to reach $467 billion by 2030, driven by novel modalities like ADCs and bispecifics, but growth will slow due to patent expirations for key drugs like Keytruda and Lynparza. R&D is shifting, with novel modalities accounting for 33% of clinical trials in 2025. The industry is also seeing broader innovation and investment, with new blockbuster contenders emerging across multiple therapeutic areas.
China's regulatory reforms since 2015 have streamlined clinical trial and drug approval processes, accelerating development of advanced therapies like CAR-T and bispecific antibodies. These changes have boosted investor confidence and created opportunities for global pharmaceutical partnerships with Chinese biotech companies that have innovative pipelines but lack international marketing capabilities.
InSilico Medicine and Eli Lilly have entered a major AI drug discovery collaboration potentially worth $2.75 billion, with Lilly gaining exclusive rights to develop preclinical oral therapies. InSilico will receive $115 million upfront plus milestone payments and royalties. The deal reflects increasing pharmaceutical industry adoption of AI platforms to accelerate drug development.
YolTech Therapeutics received FDA approval for its IND application for YOLT-202, an in vivo gene-editing therapy for Alpha-1 Antitrypsin Deficiency. Interim data from an ongoing trial showed rapid increases in AAT levels to normal range with favorable safety.
The global next generation drug conjugates market is projected to grow from $3.9 billion in 2026 to $10.9 billion by 2033 at 15.3% CAGR, while the radionuclide drug conjugate segment is forecast to reach $20.22 billion by 2032 at 9.6% CAGR.
Roche signed an agreement to invest $478 million in Korea clinical trials over five years, marking the largest foreign pharmaceutical investment. Korean companies are also securing pre-approval licensing deals globally, demonstrating growing competitiveness.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07716579 |
Assessment of Endocrine and Metabolic Late Effects After Childhood Brain Tumor Treatment |
COMPLETED | NA |
| NCT07703683 |
Myokines as Potential Biomarkers and Drivers of Sarcopenia in Metabolic and Endocrine Diseases |
RECRUITING | |
| NCT07699380 |
METabolic MODulation to Enhance Insulin Sensitivity and Mitochondrial Function in Type 1 Diabetes (MetMod-T1D) |
RECRUITING | PHASE2 |
| NCT07646015 |
Validate Smart Breath Analyzer as Screening Tool for Diabetic, Hepatic, Renal, Lung, and Other Metabolic Disorders |
COMPLETED | |
| NCT07576374 |
Specificities of Atypical Non AutoImmune Diabetes (ANAID) in the French West Indies |
NOT_YET_RECRUITING | |
| NCT07547098 |
Study on Construction of Whole Lifecycle Cohort, Big Data Management and Clinical Prognosis of Cardio-Renal-Metabolic (CKM) Syndrome |
RECRUITING | |
| NCT07534670 |
Early Pregnancy Lifestyle and Glucose Patterns: A Substudy of TOFFFY |
NOT_YET_RECRUITING | NA |
| NCT07356557 |
Evaluation of Therapeutic Adherence Among Patients Followed in the Department of Hereditary Metabolic Diseases at Necker Hospital |
RECRUITING | |
| NCT07343336 |
Landscape of Gout in French Polynesia. |
RECRUITING | |
| NCT07263269 |
Comparing Dumping Symptoms and Quality of Life 6 Months After Sleeve Gastrectomy With or Without Transit Bipartition in Adults With Obesity |
ACTIVE_NOT_RECRUITING | NA |
